See more : Gartner, Inc. (IT) Income Statement Analysis – Financial Results
Complete financial analysis of Aditxt, Inc. (ADTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aditxt, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Embrace Change Acquisition Corp. (EMCG) Income Statement Analysis – Financial Results
- Pan African Resources PLC (PAFRF) Income Statement Analysis – Financial Results
- ANGLE plc (AGL.L) Income Statement Analysis – Financial Results
- Dayu Irrigation Group Co.,Ltd. (300021.SZ) Income Statement Analysis – Financial Results
- KPX Holdings Co.,Ltd. (092230.KS) Income Statement Analysis – Financial Results
Aditxt, Inc. (ADTX)
About Aditxt, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 645.18K | 933.72K | 105.03K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.84K | 766.78K | 77.98K | 17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -111.66K | 166.94K | 27.06K | -17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -17.31% | 17.88% | 25.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.07M | 7.27M | 5.04M | 937.97K | 175.44K | 525.00K | 0.00 |
| General & Administrative | 18.61M | 15.99M | 22.08M | 7.85M | 5.69M | 5.04M | 851.94K |
| Selling & Marketing | 269.28K | 1.85M | 334.98K | 81.99K | 551.00 | 39.84K | -638.96K |
| SG&A | 18.88M | 17.84M | 22.42M | 7.93M | 5.70M | 5.08M | 212.99K |
| Other Expenses | 0.00 | 58.96K | 14.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.95M | 25.10M | 27.46M | 8.87M | 5.87M | 5.61M | 212.99K |
| Cost & Expenses | 26.71M | 25.87M | 27.54M | 8.87M | 5.87M | 5.61M | 212.99K |
| Interest Income | 10.17K | 57.35K | 3.10K | 563.00 | 1.93K | 0.00 | 0.00 |
| Interest Expense | 6.39M | 2.29M | 1.94M | 310.08K | 1.93K | 79.77K | 0.00 |
| Depreciation & Amortization | 542.58K | 535.98K | 476.24K | 17.77K | 5.87M | 5.61M | 851.94K |
| EBITDA | -25.46M | -24.83M | -43.96M | -8.85M | 45.00K | 0.00 | 638.96K |
| EBITDA Ratio | -3,945.89% | -2,600.78% | -25,663.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26.06M | -24.94M | -27.43M | -8.87M | -5.87M | -5.61M | -212.99K |
| Operating Income Ratio | -4,039.58% | -2,670.64% | -26,120.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.33M | -2.17M | -4.44M | -277.02K | 43.07K | -79.77K | 0.00 |
| Income Before Tax | -32.39M | -27.65M | -46.37M | -9.15M | -5.83M | -5.69M | -212.99K |
| Income Before Tax Ratio | -5,020.40% | -2,961.28% | -44,148.91% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 543.94K | 1.94M | 310.08K | 1.93K | -161.14K | -851.94K |
| Net Income | -32.38M | -28.19M | -48.31M | -9.46M | -5.83M | -5.69M | -212.99K |
| Net Income Ratio | -5,018.92% | -3,019.53% | -45,994.56% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| EPS Diluted | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| Weighted Avg Shares Out | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
| Weighted Avg Shares Out (Dil) | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court's approval allows transaction with Aditxt to proceed, subject to other closing conditions HALIFAX, Nova Scotia, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc....
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO ,...
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today provided an update to its shareholders on the utilization of its Equity Line of Credit (“ELOC”) and At-the-Market...
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (“Appili”). Shareholders of...
Appili Therapeutics Announces Results of Special Meeting of Shareholders
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on...
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), has secured voting agreements with certain of...
Evofem Secures Investor Support for Proposed Merger through Voting Agreements
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders and convertible noteholders to ensure they will vote in favor...
Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A session with CEO Amro Albanna this Friday, November 1, 2024,...
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone under the Amended and Restated Merger Agreement, as amended (the “A&R...
Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced a virtual fireside chat set for October 28, 2024, at 11:30 AM Eastern Time. The event will...
Source: https://incomestatements.info
Category: Stock Reports